Development of a Costimulatory Molecule Signature to Predict Prognosis, Immune Landscape, and Response to Immune Therapy for Hepatocellular Carcinoma

<div>Biological processes and pathways based on risk model. Bar plot graph of (a) GO enrichment and (b) KEGG enrichment for differentially costimulatory molecule genes between both risk groups.</div>

Disease Markers

fig6

Figure 6

Figure 6: Development of a Costimulatory Molecule Signature to Predict Prognosis, Immune Landscape, and Response to Immune Therapy for Hepatocellular Carcinoma 

Figure 6 | Development of a Costimulatory Molecule Signature to Predict Prognosis, Immune Landscape, and Response to Immune Therapy for Hepatocellular Carcinoma 